BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Uroplasty, Inc. (UPI) Executives Unfazed Over Competition From Allergan Inc. (AGN)'s Botox to Treat Overactive Bladder


1/28/2013 8:36:22 AM

Botox is the miracle wrinkle-remover but if many were expecting that its approval to treat overactive bladder would cause wrinkles on the foreheads of senior management at Minnesota incontinence treatment company Uroplasty, they were mistaken. At least for now. In a conference call with analysts to discuss the company’s third fiscal quarter earnings Thursday, Uroplasty CEO Dave Kaysen said the company had been expecting an approval and wasn’t surprised that it came in early 2013. Kaysen went on to paint broad picture of “a high tide lifts all boats” scenario. We know today that fully two-thirds of the people in the US with OAB do not currently seek treatments for their symptoms. The more patients that visit the doctor seeking improvement, the better for all of the solutions, including Urgent PC. Botox is clearly not for every patient, especially when you consider the published potential side effects, which include urinary tract infections and urinary retention. We believe this will open opportunities for Urgent PC as an effective treatment with few, if any, side effects. So in summary, we anticipate that Botox and Allergan will expand the market, and that we will benefit from that growth, with what we believe is an outstanding product for treating overactive bladder, that being our Urgent PC. Sales of the company’s Urgent PC neuromodulation have been going from strength to strengthas the company has been successful in overcoming reimbursement challenges. In the third fiscal quarter ended Dec. 31, sales of Urgent PC jumped 37 percent in the U.S. Total sales of the company was $5.6 million, up 5 percent from the same quarter in 2011.

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->